Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1:: Role of 17-AAG hydroquinone in heat shock protein 90 inhibition.

被引:144
作者
Guo, WC
Reigan, P
Siegel, D
Zirrolli, J
Gustafson, D
Ross, D
机构
[1] Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA
[2] Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA
关键词
D O I
10.1158/0008-5472.CAN-05-2029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have examined the role of NAD(P)H:quinone oxidoreductase 1 (NQO1) in the bioreductive metabolism of 17-allylamino-demethoxygeldanamycin (17-AAG). High-performance liquid chromatography (HPLC) analysis of the metabolism of 17-AAG by recombinant human NQO1 revealed the formation of a more polar metabolite 17-AAGH(2). The formation of 17-AAGH2 was NQ01 dependent, and its formation could be inhibited by the addition of 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione (ES936), a mechanism-based (suicide) inhibitor of NQO1. The reduction of 17-AAG to the corresponding hydroquinone 17-AAGH2 was confirmed by tandem liquid chromatography-mass spectrometry. 17-AAGH2 was relatively stable and only slowly underwent autooxidation back to 17-AAG over a period of hours. To examine the role of NQ01 in 17-AAG metabolism in cells, we used an isogenic pair of human breast cancer cell lines differing only in NQO1 levels. MDA468 cells lack NQ01 due to a genetic polymorphism, and MDA468/NQ16 cells are a stably transfected clone that express high levels of NQ01 protein. HPLC analysis of 17-AAG metabolism using cell sonicates and intact cells showed that 17-AAGH2 was formed by MDA468/NQ16 cells, and formation of 17-AAGH2 could be inhibited by ES936. No 17-AAGH2 was detected in sonicates or intact MDA468 cells. Following a 4-hour treatment with 17-AAG, the MDA468/NQ16 cells were 12-fold more sensitive to growth inhibition compared with MDA468 cells. More importantly, the increased sensitivity of MDA468/NQ16 cells to 17-AAG could be abolished if the cells were pretreated with ES936. Cellular markers of heat shock protein (Hsp) 90 inhibition, Hsp70 induction, and Raf-1 degradation were measured by immunoblot analysis. Marked Hsp70 induction and Raf-1 degradation was observed in MDA468/NQ16 cells but not in MDA468 cells. Similarly, downstream Raf-1 signaling molecules mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) kinase and ERK also showed decreased levels of phosphorylation in MDA468/NQ16 cells but not in MDA468 cells. The ability of 17-AAG and 17-AAGH2 to inhibit purified yeast and human Hsp90 ATPase activity was examined. Maximal 17-AAG-induced ATPase inhibition was observed in the presence of NQO1 and could be abrogated by ES936, showing that 17-AAGH(2) was a more potent Hsp90 inhibitor compared with 17-AAG. Molecular modeling studies also showed that due to increased hydrogen bonding between the hydroquinone and the Hsp90 protein, 17-AAGH2 was bound more tightly to the ATP-binding site in both yeast and human Hsp90 models. In conclusion, these studies have shown that reduction of 17-AAG by NQO1 generates 17-AAGH(2), a relatively stable hydroquinone that exhibits superior Hsp90 inhibition.
引用
收藏
页码:10006 / 10015
页数:10
相关论文
共 31 条
[1]  
Bagatell R, 2004, MOL CANCER THER, V3, P1021
[2]  
BEALL HD, 1994, CANCER RES, V54, P3196
[3]   Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin [J].
Beall, HD ;
Liu, YF ;
Siegel, D ;
Bolton, EM ;
Gibson, NW ;
Ross, D .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (05) :645-652
[4]   Hsp90: an emerging target for breast cancer therapy [J].
Beliakoff, J ;
Whitesell, L .
ANTI-CANCER DRUGS, 2004, 15 (07) :651-662
[5]  
Cullen JJ, 2003, CANCER RES, V63, P5513
[6]   Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H: Quinone oxidoreductase-directed antitumor quinones: Evaluation of the activity of RH1 [J].
Dehn, DL ;
Winski, SL ;
Ross, D .
CLINICAL CANCER RESEARCH, 2004, 10 (09) :3147-3155
[7]   Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts [J].
Eiseman, JL ;
Lan, J ;
Lagattuta, TF ;
Hamburger, DR ;
Joseph, E ;
Covey, JM ;
Egorin, MJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (01) :21-32
[8]  
Ernster L, 1967, Methods in enzymology, P309, DOI DOI 10.1016/0076-6879(67)10059-1
[9]  
GUO W, 2005, P AACR, V46, P4936
[10]   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative [J].
Hollingshead, M ;
Alley, M ;
Burger, AM ;
Borgel, S ;
Pacula-Cox, C ;
Fiebig, HH ;
Sausville, EA .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 56 (02) :115-125